Sanara MedTech Inc. Announces The Publication of A 5,335 Patient Study Demonstrating A Significant Reduction In Surgical Site Infections When Activated Collagen (CellerateRX Surgical Powder) Was Used To Promote Wound Healing
Portfolio Pulse from Benzinga Newsdesk
Sanara MedTech Inc. announced the publication of a study in the Journal of Surgery showing that its product, CellerateRX Surgical Powder, significantly reduces surgical site infections in elective surgeries. The retrospective study of 5,335 patients demonstrated a 59% reduction in infection rates, with a 69% decrease in clean cases. The study, partially funded by a subsidiary of Sanara, supports the use of CellerateRX across various surgical specialties to improve patient outcomes and reduce healthcare costs.
November 30, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanara MedTech's CellerateRX Surgical Powder shown to reduce surgical site infections by 59% in a study, potentially boosting its market adoption and sales.
The publication of a positive study in a reputable journal typically has a favorable impact on the company's product credibility and can lead to increased adoption by healthcare providers. This can result in higher sales and revenue for Sanara MedTech, thus potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100